Summary

Global Biological PCR Technology Market was valued at USD 13.12 Billion in 2024 and is expected to reach USD 20.14 Billion by 2030 with a CAGR of 7.36% during the forecast period. The global biological PCR technology market is driven by the increasing demand for precise and rapid diagnostics, particularly in infectious diseases, cancer, and genetic disorders. PCR’s ability to detect minute amounts of DNA and RNA with high sensitivity makes it invaluable in clinical and research applications. The rise in global infectious diseases, such as COVID-19, and the need for pandemic preparedness have significantly boosted PCR testing adoption. Advancements in PCR technologies, including real-time and digital PCR, have expanded its applications in personalized medicine, oncology, and genetic testing. Growing awareness of early disease detection and the rise of genetic research continue to support the demand for PCR-based solutions, further fuelling market growth.
Key Market Drivers
Increasing Demand for Accurate and Rapid Diagnostics
The global biological PCR technology market is experiencing significant growth due to the increasing demand for accurate and rapid diagnostics in both clinical and research settings. PCR technology has revolutionized diagnostics by offering high sensitivity and specificity in detecting pathogens, genetic mutations, and various disease biomarkers. Traditional diagnostic techniques, like culture-based methods or serological tests, often lack the speed and precision required for timely medical intervention. In March 2023, Jiangsu Bioperfectus Technologies Co., Ltd. introduced two new PCR products: the Mycoplasma Hominis Real-Time PCR Kit and the Treponema Pallidum Real-Time PCR Kit. When paired with our extraction solution, these kits offer a comprehensive Total PCR Solution for the early detection of sexually transmitted diseases that impact a large number of individuals.
PCR’s ability to detect low levels of DNA or RNA in a sample means that it can provide results quickly, allowing healthcare providers to diagnose infectious diseases, such as COVID-19, HIV, and tuberculosis, more accurately and efficiently. With the increasing complexity of disease management, especially in oncology and genetic disorders, PCR-based diagnostics are gaining significant traction. The technology also provides faster results than conventional testing methods, which is critical for decision-making in situations where time-sensitive interventions can significantly improve patient outcomes. This demand for quick, accurate testing in clinical settings is driving the adoption of PCR technology in hospitals, diagnostic laboratories, research institutions, and point-of-care settings. As healthcare systems across the globe focus more on early detection and effective management of diseases, the use of PCR technology continues to rise, fueling the market’s expansion.
Advancements in PCR Technology
Technological advancements in PCR technology have been crucial in accelerating the growth of the biological PCR technology market. Initially, conventional PCR methods were used for amplifying DNA samples for basic research and diagnostics. However, with the advancement of real-time PCR (RT-PCR), digital PCR, and multiplex PCR, the scope and precision of PCR testing have expanded significantly. Real-time PCR, for example, allows the continuous monitoring of the amplification process, enabling quantitative measurement of target DNA or RNA. In November 2022, Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, and NuProbe USA, a company specializing in genomics and molecular diagnostics, today announced a licensing and product development agreement. As part of the agreement, NuProbe USA will exclusively license its allele enrichment technologies to Bio-Rad for the development of multiplexed digital PCR assays. This technology will enhance Bio-Rad's oncology product offerings, enabling highly sensitive and multiplexed mutation detection to support translational research, therapy selection, and disease monitoring.
This is particularly useful in research and diagnostics, where accurate viral load measurements are necessary for monitoring infections like HIV, hepatitis, and SARS-CoV-2. Digital PCR, on the other hand, offers unparalleled sensitivity and precision, detecting rare mutations and low-abundance genetic material, which is essential for early detection of diseases such as cancer. Multiplex PCR allows simultaneous amplification and detection of multiple genetic targets in a single test, improving diagnostic efficiency and reducing test turnaround times. These innovations have enabled PCR to become indispensable in areas like oncology, personalized medicine, and genetic testing. As the technology continues to evolve, the introduction of automated and more cost-effective PCR systems further enhances market accessibility, driving wider adoption across various healthcare sectors. The growing focus on miniaturization has led to the development of portable PCR systems, making it possible for diagnostic testing to be conducted in remote or resource-limited settings, further expanding PCR technology’s reach.
Rising Prevalence of Infectious Diseases
The increasing global prevalence of infectious diseases is one of the key factors driving the growth of the biological PCR technology market. Infectious diseases, particularly viral infections, represent a major public health threat worldwide. The rapid spread of pathogens and emerging new diseases require diagnostic systems capable of identifying infections quickly and accurately. PCR technology’s high sensitivity allows for the detection of even trace amounts of genetic material, enabling early diagnosis and timely intervention. For instance, during the COVID-19 pandemic, PCR-based molecular tests became the cornerstone of global diagnostic efforts, enabling healthcare professionals to identify infected individuals quickly and accurately, helping curb the spread of the virus. Beyond COVID-19, PCR technology plays a vital role in the detection of various other infectious diseases such as HIV, hepatitis, influenza, and tuberculosis. As the global population continues to face emerging infectious diseases, coupled with the growing threat of antimicrobial resistance, the need for accurate and reliable diagnostics becomes increasingly critical. PCR-based testing allows for rapid identification of pathogens, allowing for quicker clinical decision-making and more effective patient management. The rising incidence of infectious diseases, combined with the growing awareness of the need for early and precise diagnostics, continues to drive the adoption of PCR technology in both developed and developing healthcare settings.
Growing Demand for Personalized Medicine
Personalized medicine is increasingly recognized as a promising approach to treating patients based on their individual genetic makeup. This shift towards more tailored treatment regimens has significantly boosted the adoption of biological PCR technology. PCR plays an integral role in identifying genetic mutations, which can guide the selection of therapies that are most likely to be effective for an individual. In oncology, for example, PCR is used to detect specific genetic mutations in tumor cells, which can help identify patients who are most likely to benefit from targeted therapies or immunotherapies. Personalized medicine also requires regular monitoring of biomarkers to evaluate treatment efficacy, and PCR is crucial for these assessments due to its ability to detect even low quantities of genetic material. Genetic testing is becoming increasingly important not only in cancer treatment but also in managing chronic conditions such as cardiovascular diseases, diabetes, and neurological disorders. The demand for personalized medicine continues to rise, driven by the growing availability of genomic data and the increasing emphasis on precision healthcare. As more patients and healthcare providers recognize the benefits of personalized treatment plans, PCR technology becomes indispensable in identifying the right therapeutic interventions, further fueling the growth of the market.
Key Market Challenges
High Cost of PCR Equipment and Consumables
One of the significant challenges facing the global biological PCR technology market is the high cost of PCR equipment and consumables. The advanced PCR systems, including real-time PCR, digital PCR, and multiplex PCR, are often expensive to purchase and maintain, making them financially challenging for small and medium-sized healthcare facilities, laboratories, and research institutions. In addition to the initial high capital investment, the cost of reagents, consumables, and maintenance is substantial, which can increase the overall cost of testing. As a result, many resource-limited settings, particularly in low-income countries, may face barriers to adopting PCR technology. This financial burden may limit the widespread adoption of PCR, particularly in regions where cost-efficiency is a priority. The continuous need to replenish reagents, replace components, and maintain the system can create ongoing financial constraints. This challenge necessitates the development of more affordable PCR systems and reagents to improve accessibility and drive broader market growth.
Complexity of PCR Procedures and Need for Skilled Personnel
PCR testing, while highly effective, can be a technically complex procedure that requires skilled personnel to operate. The preparation of samples, setting up the PCR system, performing the amplification process, and interpreting the results require a high level of expertise. This challenge is particularly evident in developing countries or rural areas where there may be a shortage of trained healthcare professionals or laboratory technicians. Inadequate training can lead to inaccurate results, which may undermine the reliability of PCR-based testing. Due to the complexity of PCR systems, it may take time for healthcare professionals to become proficient in their use. As the demand for PCR technology increases, especially in resource-limited settings, there is a pressing need for standardized training programs and certifications to ensure consistent and accurate results across the board. Addressing this challenge would require investments in workforce training, automation, and user-friendly PCR systems to simplify testing procedures and reduce reliance on skilled labor.
Limitations in Detection Sensitivity and Specificity
Although PCR technology is known for its high sensitivity and specificity, there are certain limitations regarding its ability to accurately detect rare genetic mutations, mutations in heterogeneous samples, or subtle variations in pathogen strains. For instance, PCR may sometimes generate false-negative results if the target DNA or RNA concentration is below the detection threshold or if there are issues with sample quality. Some complex genetic disorders may be challenging to detect using traditional PCR methods, leading to the need for more advanced techniques such as next-generation sequencing (NGS). PCR-based systems may also struggle to differentiate between very similar pathogen strains, which could lead to misidentification. As the demand for PCR testing expands, especially in critical areas such as personalized medicine and infectious disease detection, improving the sensitivity and specificity of PCR technology becomes a key challenge. Ongoing research and development are essential to overcome these limitations and enhance the precision and accuracy of PCR tests.
Key Market Trends
Expanding Applications in Research and Clinical Trials
PCR technology has become an indispensable tool in research and clinical trials, driving its widespread adoption across various scientific disciplines. In molecular biology, PCR is used to amplify specific DNA sequences for genetic analysis, which is essential for studies related to gene expression, genetic mutations, and disease pathogenesis. The versatility of PCR makes it applicable in a wide range of research fields, including microbiology, genomics, and epidemiology. In April 2023, Promega Corporation announced the awarding of USD 15,000 grants to researchers utilizing real-time quantitative PCR (qPCR). In addition, Promega will provide these researchers with VIP technical support and personalized training.
PCR is crucial in clinical trials, where it is used to monitor disease progression, assess the efficacy of new treatments, and identify potential biomarkers for disease. Pharmaceutical companies and biotechnology firms rely heavily on PCR technology to ensure that their drug candidates are effective and safe for patients. PCR’s ability to provide rapid, high-throughput genetic analysis also accelerates the pace of research and clinical trials, which is vital in the fast-moving healthcare sector. As the demand for faster and more efficient drug development increases, the reliance on PCR technology in research and clinical trials will continue to grow, further expanding its market.
Technological Integration with Digital Health and Point-of-Care Testing
The integration of PCR technology with digital health solutions and point-of-care (POC) testing is a key driver of the biological PCR technology market. The rise of digital health technologies, including telemedicine, electronic health records (EHRs), and mobile health applications, has transformed the way healthcare is delivered. PCR technology, when integrated with these digital tools, enables healthcare providers to access real-time diagnostic results, improve clinical decision-making, and provide better patient care. In March 2023, the U.S. Department of Health and Human Services announced that the U.S. Food and Drug Administration (FDA) had granted clearance for Simplexa COVID-19 and Flu A/B Direct. This real-time RT-PCR system is a molecular diagnostic test designed for the direct amplification and detection of SARS-CoV-2 (COVID-19 virus), influenza A, and influenza B RNA from nasopharyngeal swab specimens without the need for nucleic acid extraction.
Point-of-care PCR systems, which can deliver results outside traditional laboratory settings, have become increasingly important, particularly in emergency situations or remote areas. These systems enable clinicians to obtain rapid diagnostic results without waiting for results from central laboratories, leading to faster treatment decisions. As the healthcare industry shifts toward more patient-centric care, point-of-care PCR testing is becoming more widely adopted in settings such as urgent care centers, physician offices, and home healthcare services. The ability to perform PCR tests at the point of care, combined with the advantages of digital health integration, is driving further adoption of PCR technology.
Segmental Insights
Product Type Insights
Based on the Product Type, reagents have a more dominant role due to their central importance in PCR testing procedures. Reagents, which include enzymes, primers, buffers, and nucleotides, are the core elements required for amplifying DNA or RNA in PCR reactions. Their quality and consistency directly influence the accuracy, sensitivity, and reliability of PCR results, making them a crucial factor in the performance of PCR systems.
The market for reagents has grown considerably over the years as PCR technology has become a standard method for diagnostic testing, genetic research, and clinical applications. Reagents are needed in almost every PCR reaction, whether it’s for real-time PCR, digital PCR, or multiplex PCR, further solidifying their role in the PCR workflow. With the increasing demand for personalized medicine, cancer research, and genetic testing, the need for high-quality and highly specific PCR reagents has surged. PCR testing involves the precise amplification of target DNA or RNA, and any issues with reagent quality can lead to false positives, false negatives, or suboptimal results, which is why the market continues to prioritize high-quality reagents for various applications. Reagents are more frequently consumed than consumables in the PCR process. PCR tests often require multiple reagent sets depending on the number of samples and tests being conducted, leading to frequent purchases and replenishment. The need for reagents is thus driven by factors such as the volume of testing in clinical laboratories, diagnostic centers, and research facilities, as well as advancements in PCR technology that require more specialized or customized reagents. The growing use of PCR in various fields like oncology, infectious disease diagnostics, and genetic analysis further elevates the demand for specialized reagents tailored to specific tests and research needs.
End Use Insights
Based on the end use segment, molecular testing laboratories are currently dominating, largely due to their specialized focus on molecular diagnostics and the increasing demand for genetic and infectious disease testing. These laboratories play a central role in implementing PCR technology, as molecular testing relies heavily on the precise amplification and detection of DNA or RNA to identify genetic markers, pathogens, mutations, and other molecular markers. The need for such highly accurate diagnostic methods has spurred the growth of molecular testing laboratories, which are at the forefront of this market.
Molecular testing laboratories are increasingly sought after due to the rise in demand for genetic testing, cancer diagnostics, infectious disease detection, and personalized medicine. As PCR technology is the gold standard for detecting specific genetic sequences and pathogens, these laboratories are essential for conducting tests like real-time PCR, digital PCR, and multiplex PCR. Molecular testing is critical in identifying rare genetic mutations and variations, assessing viral loads in diseases such as HIV and hepatitis, and determining the presence of bacterial or viral pathogens like tuberculosis, influenza, and COVID-19. The integration of PCR technology allows these laboratories to provide highly accurate and reliable results, which are crucial for disease diagnosis, prognosis, and treatment planning.
The demand for molecular testing has surged in recent years, primarily driven by the increased awareness of genetic disorders, the growing prevalence of infectious diseases, and the expanding need for personalized medicine. PCR-based molecular testing is widely used in clinical diagnostics for conditions like cancer, genetic disorders, and infections, providing valuable information for early diagnosis, monitoring, and treatment. With the rise of personalized medicine, which tailors treatments based on a patient's genetic profile, molecular testing has become an indispensable part of patient care. For example, PCR is frequently used in oncology to identify genetic mutations in tumor cells, which can inform decisions regarding targeted therapies or immunotherapies. As molecular testing becomes more integrated into routine medical practice, the demand for PCR technology continues to grow.
Regional Insights
North America was dominating the global Biological PCR Technology Market. This dominance is primarily driven by the high level of technological advancements, strong healthcare infrastructure, substantial investments in research and development, and an increasing demand for molecular diagnostics in the region. North America, particularly the United States, is home to some of the largest and most influential pharmaceutical and biotechnology companies, academic research institutions, and clinical laboratories. The U.S. has been at the forefront of adopting PCR technology for a wide range of applications, from disease diagnostics to genetic research, further solidifying its leadership in the global market.
One of the key factors contributing to North America's dominance in the PCR technology market is the region's advanced healthcare system. The healthcare infrastructure in North America is highly developed, with a robust network of hospitals, diagnostic centers, and molecular testing laboratories equipped with state-of-the-art PCR systems. PCR technology is widely used in hospitals and diagnostic centers for the detection of infectious diseases such as COVID-19, HIV, and tuberculosis, as well as genetic testing for cancer, genetic disorders, and personalized medicine. The region's healthcare providers rely heavily on PCR-based diagnostics due to their high accuracy, sensitivity, and ability to detect a wide range of genetic conditions and pathogens. The need for reliable and rapid diagnostic tests has further increased the adoption of PCR technology in North America.
Key Market Players
• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories Inc.
• QIAGEN GmbH
• Takara Bio Inc.
• Merck KGaA
• Bioneer Corporation
• Illumina, Inc.
• Promega Corporation
• Eppendorf SE
Report Scope:
In this report, the Global Biological PCR Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Biological PCR Technology Market, By Product Type:
o Reagents
o Consumables
• Biological PCR Technology Market, By End Use:
o Diagnostic Laboratories
o Molecular Testing Laboratories
• Biological PCR Technology Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Biological PCR Technology Market.
Available Customizations:
Global Biological PCR Technology market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Biological PCR Technology Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type (Reagents and Consumables)
5.2.2. By End Use (Diagnostic Laboratories and Molecular Testing Laboratories)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Biological PCR Technology Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type
6.2.2. By End Use
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Biological PCR Technology Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product Type
6.3.1.2.2. By End Use
6.3.2. Canada Biological PCR Technology Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product Type
6.3.2.2.2. By End Use
6.3.3. Mexico Biological PCR Technology Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product Type
6.3.3.2.2. By End Use
7. Europe Biological PCR Technology Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By End Use
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Biological PCR Technology Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product Type
7.3.1.2.2. By End Use
7.3.2. United Kingdom Biological PCR Technology Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product Type
7.3.2.2.2. By End Use
7.3.3. Italy Biological PCR Technology Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product Type
7.3.3.2.2. By End Use
7.3.4. France Biological PCR Technology Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product Type
7.3.4.2.2. By End Use
7.3.5. Spain Biological PCR Technology Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product Type
7.3.5.2.2. By End Use
8. Asia-Pacific Biological PCR Technology Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By End Use
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Biological PCR Technology Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product Type
8.3.1.2.2. By End Use
8.3.2. India Biological PCR Technology Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product Type
8.3.2.2.2. By End Use
8.3.3. Japan Biological PCR Technology Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product Type
8.3.3.2.2. By End Use
8.3.4. South Korea Biological PCR Technology Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product Type
8.3.4.2.2. By End Use
8.3.5. Australia Biological PCR Technology Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product Type
8.3.5.2.2. By End Use
9. South America Biological PCR Technology Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By End Use
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Biological PCR Technology Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product Type
9.3.1.2.2. By End Use
9.3.2. Argentina Biological PCR Technology Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product Type
9.3.2.2.2. By End Use
9.3.3. Colombia Biological PCR Technology Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product Type
9.3.3.2.2. By End Use
10. Middle East and Africa Biological PCR Technology Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product Type
10.2.2. By End Use
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Biological PCR Technology Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product Type
10.3.1.2.2. By End Use
10.3.2. Saudi Arabia Biological PCR Technology Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product Type
10.3.2.2.2. By End Use
10.3.3. UAE Biological PCR Technology Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product Type
10.3.3.2.2. By End Use
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. Competitive Landscape
14.1. Thermo Fisher Scientific Inc.
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (As Reported)
14.1.5. Recent Developments
14.1.6. Key Personnel Details
14.1.7. SWOT Analysis
14.2. Agilent Technologies, Inc.
14.3. Bio-Rad Laboratories Inc.
14.4. QIAGEN GmbH
14.5. Takara Bio Inc.
14.6. Merck KGaA
14.7. Bioneer Corporation
14.8. Illumina, Inc.
14.9. Promega Corporation
14.10. Eppendorf SE
15. Strategic Recommendations
16. About Us & Disclaimer